Welcome to our dedicated page for Northwest Bio news (Ticker: NWBO), a resource for investors and traders seeking the latest updates and insights on Northwest Bio stock.
Northwest Biotherapeutics, Inc. (NWBO) generates news as a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers. Its updates often focus on progress with DCVax-L for glioblastoma, DCVax-Direct for inoperable solid tumors, and broader dendritic cell technology initiatives. Because the company is advancing living-cell immunotherapies and building specialized manufacturing capacity, its announcements can be particularly relevant for investors and observers following cancer immunotherapy and cell therapy manufacturing.
News about Northwest Biotherapeutics commonly covers clinical development milestones, such as the completion of a 331-patient Phase III trial of DCVax-L for glioblastoma, publication of trial results in JAMA Oncology, and the submission and review status of its Marketing Authorization Application in the UK. The company also issues releases on scientific presentations, including talks on next-generation dendritic cell treatments and factors that may enhance anti-tumor responses.
Another major category of NWBO news involves manufacturing and infrastructure. The company reports on the development of its Flaskworks closed manufacturing system, the move from prototype optimization to fabrication of GMP-compliant units, and construction of a Grade C manufacturing suite at its Sawston, UK facility. These updates describe efforts to scale production capacity and shift from Grade B to Grade C clean rooms to support potential larger patient volumes.
Corporate and financial developments also feature prominently in Northwest Biotherapeutics’ news flow. Examples include convertible note financings, commercial loan agreements, standby equity facilities, in-licensing of dendritic cell technology and intellectual property portfolios, and the acquisition of Advent BioServices Ltd. Governance and organizational updates, such as board appointments and annual meeting voting results, are also disclosed.
This news page aggregates these types of announcements so readers can follow regulatory, clinical, manufacturing, financing, and governance developments related to NWBO in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Northwest Biotherapeutics (OTCQB: NWBO) has received a Manufacturing and Importation Authorization (MIA) license from the Medicines and Healthcare Products Regulatory Agency (MHRA) for commercial manufacturing of cell therapy products at its Sawston, U.K. facility. This license, among the first of its kind in the U.K., enables global product export and is a significant step toward regulatory approval for NW Bio's lead product, DCVax®-L. Linda Powers, CEO, emphasized the milestone's importance for global operations, while Advent BioServices underscored the rigorous preparations that met high manufacturing standards over three years.
Northwest Biotherapeutics (OTCQB: NWBO) announced it has no banking relationship with Silicon Valley Bank (SVB) following SVB's shutdown. The company confirmed it had no funds deposited at SVB and believes it will not be affected by this situation, as it has diversified its banking relationships. NW Bio will monitor the situation and review its banking ties. The company is focused on developing DCVax® personalized immune therapies for cancer and has completed a Phase III trial for Glioblastoma multiforme. NW Bio aims to treat cancers more effectively than traditional therapies.
Northwest Biotherapeutics (NWBO) reported a strong turnout at its Annual Meeting on December 30, 2022, with 78% of shares voted. All six proposals received over 90% approval, including re-elections of directors and an increase of authorized common shares by 500 million. The company highlighted achievements in 2022, notably positive Phase 3 trial results for DCVax-L for Glioblastoma. Looking ahead, NWBO aims to secure a commercial manufacturing license and continue expanding operations in 2023, emphasizing ongoing progress in cancer immunotherapy.
Northwest Biotherapeutics has filed a lawsuit against prominent market makers, alleging they engaged in market manipulation via spoofing, causing significant stock price declines. The company claims these actions coincided with its efforts to raise funds for its groundbreaking DCVax personalized cancer vaccines. A notable incident occurred on May 10, 2022, resulting in an 82% drop in share price and a loss of $1.6 billion in market cap, despite positive clinical trial results. The lawsuit aims to hold these market makers accountable and restore transparency.
Northwest Biotherapeutics (NWBO) announced significant results from its Phase III trial of DCVax®-L for glioblastoma. The study demonstrated increased median survival and a 'long tail' of survival for both newly diagnosed and recurrent patients. Median Overall Survival (mOS) for newly diagnosed patients was 19.3 months, compared to 16.5 months for controls. For recurrent patients, mOS was 13.2 months versus 7.8 months. The trial met primary and secondary endpoints, encouragingly published in JAMA Oncology. Regulatory approval preparations for DCVax®-L are underway.
Northwest Biotherapeutics (NWBO) announced the approval from the UK MHRA for its Pediatric Investigation Plan (PIP) for DCVax-L, a personalized immune therapy targeting solid tumors. This PIP approval is critical for advancing the company's application for a Marketing Authorization Application (MAA) for adult patients. The PIP includes two clinical trials for pediatric high grade glioma patients, with a primary focus on overall survival compared to external controls. The company submitted the PIP in February 2022 and received final approval on August 17, 2022.